FDA-approved vs compounded GLP-1 medications

The direct answer

FDA says compounded drugs are not FDA-approved and are not the same as FDA-approved generic drugs. FDA also reminds telehealth companies not to describe a compounded GLP-1 drug as the same as, or a generic version of, an FDA-approved product FDA telehealth compounding reminders.

FDA says compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, and separately explains that a compounded drug might be appropriate when an FDA-approved drug is not commercially available FDA concerns with unapproved GLP-1 drugs. The patient-specific reason matters, and the product should be described plainly.

What patients should not infer from familiar names

Familiar ingredient names can make different products sound closer than they are. A patient may hear semaglutide or tirzepatide and assume the same approval, dose form, route, pharmacy controls or evidence applies. That assumption can be wrong. FDA-approved product labeling belongs to the specific product named in the label. A compounded preparation needs its own explanation.

FDA has also warned telehealth companies about marketing that obscures product sourcing, such as using a telehealth brand name in a way that makes the platform look like the compounder. If a medication is compounded, the patient should know which pharmacy is responsible for the preparation and who can answer clinical questions after dispensing.

What FDA approval applies to

Approval belongs to a finished drug product with a specific manufacturer, route, dosage form, labeling and indication. It does not attach automatically to every preparation that contains the same active ingredient.

This distinction is especially important with ingredient names. Semaglutide appears in several products, but the route, dosage form and indication differ by product label.

Oral semaglutide needs careful wording

Current official labeling for Wegovy includes semaglutide tablets for oral use as well as semaglutide injection DailyMed Wegovy label. Current DailyMed labeling for Rybelsus and Ozempic tablets describes Rybelsus as semaglutide tablets for oral use, with labeling for adults with type 2 diabetes and a different product context DailyMed Rybelsus label.

The safe question is more specific: Which product is it, what route and dosage form does the label describe, what is the indication, and is the preparation FDA-approved or compounded? A compounded oral, dissolving or sublingual preparation should not be treated as equivalent to an FDA-approved tablet unless an authoritative source specifically supports that product-level claim.

Why shortage status cannot be assumed

Compounding policy can change when shortages change. In FDA’s April 1, 2026 GLP-1 compounding update, the agency stated that tirzepatide and semaglutide did not currently appear on the 503B bulks list or FDA’s drug shortage list FDA compounding policy update. FDA also describes restrictions on compounding products that are essentially copies of commercially available drugs.

For patients, the practical issue is transparency. If a clinic discusses a compounded GLP-1 medication, ask why an FDA-approved product does not meet the medical need, who compounds the medication, which pharmacy dispenses it, what instructions come with it and how a licensed clinician can answer questions after it arrives.

Dosing and shipping questions are part of safety

FDA has described concerns with compounded GLP-1 products involving dosing errors, multi-dose vials, storage during shipping, fraudulent labels and semaglutide salt forms FDA concerns with unapproved GLP-1 drugs. These are practical patient questions, not fine print.

Before starting, ask how the medication should be measured, stored and used; what to do if it arrives warm or damaged; and which clinician or pharmacy can answer questions about the label. Do not guess from instructions for a different product.

Questions to ask before accepting treatment

• Is this an FDA-approved finished drug product or a compounded preparation?
• What is the brand or product name, active ingredient, route and dosage form?
• If it is compounded, what patient-specific need is being addressed?
• Which pharmacy will dispense or compound the medication?
• What instructions come with the medication, and who answers questions after delivery?
• What are the labeled warnings, contraindications and side effects I should understand?

For a comparison of the active ingredients, read semaglutide vs tirzepatide. For the clinical review step, read what a GLP-1 evaluation may include.

Common questions